BioCentury | Nov 26, 2018
Distillery Therapeutics

Cardiovascular

...Pharmaceutical Co. Ltd., Gruppo Angelini, Incyte Corp., Medison Pharma Ltd., Otsuka Pharmaceutical Co. Ltd. and Specialised Therapeutics Australia Pty. Ltd....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...treatment-naïve patients PDUFA date September PharmaMar S.A. (Madrid:PHM) / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Specialised Therapeutics Australia Pty. Ltd....
BioCentury | May 30, 2018
Distillery Therapeutics

Neurology

...testing additional stabilizers of FAM9B G-quadruplex DNA in humanized models of ATR-X. Medac GmbH and Specialised Therapeutics Australia Pty. Ltd....
BioCentury | Mar 27, 2018
Distillery Therapeutics

Cancer; inflammation

...Pharmaceutical Co. Ltd., Gruppo Angelini, Incyte Corp., Medison Pharma Ltd., Otsuka Pharmaceutical Co. Ltd. and Specialised Therapeutics Australia Pty. Ltd....
BioCentury | Mar 13, 2018
Distillery Therapeutics

Cancer

...conjugate in additional models of TNBC. Celgene Corp., BeiGene Ltd., Biocon Ltd., Green Cross Corp., Specialised Therapeutics Australia Pty. Ltd....
...Ltd. market Abraxane, an albumin-stabilized nanoparticle formulation of paclitaxel, to treat breast cancer. Celgene, BeiGene, Specialised Therapeutics Australia...
BioCentury | Jan 26, 2018
Clinical News

PharmaMar's Zepsyre misses in Phase III for platinum-resistant ovarian cancer

...its active state. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) has exclusive, Japanese rights to Zepsyre, while Specialised Therapeutics Australia Pty. Ltd....
...see BioCentury, Dec. 29, 2016 & June 8, 2017 ). PharmaMar S.A. (Madrid:PHM), Madrid, Spain Specialised Therapeutics Australia Pty. Ltd....
...overall response rate (ORR) Status: Phase III data Milestone: NA Jaime De Leon lurbinectedin PM01183 PM1183 Zepsyre Chugai Pharmaceutical Co. Ltd. PharmaMar S.A. Specialised Therapeutics Australia Pty. Ltd. RNA...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Additional Ph III data 1H18 PharmaMar S.A. (Madrid:PHM) / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Specialised Therapeutics Australia Pty. Ltd....
BioCentury | Nov 30, 2017
Clinical News

PharmaMar reports Phase II response data for Zepsyre in Ewing's sarcoma

...overall survival (OS). Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) has exclusive, Japanese rights to Zepsyre, while Specialised Therapeutics Australia Pty. Ltd....
...targeting RNA polymerase II (Pol II) in its active state. PharmaMar S.A. (Madrid:PHM), Madrid, Spain Specialised Therapeutics Australia Pty. Ltd....
...1-year overall survival (OS) Status: Phase II data Milestone: NA Jaime De Leon lurbinectedin PM01183 PM1183 Zepsyre Chugai Pharmaceutical Co. Ltd. PharmaMar S.A. Specialised Therapeutics Australia Pty. Ltd. RNA...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...acne vulgaris Submit NDA 4Q17 PharmaMar S.A. (Madrid:PHM) / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Specialised Therapeutics Australia Pty. Ltd....
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...panel; PDUFA date 7/11/17; September PharmaMar S.A. (Madrid:PHM) / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Specialised Therapeutics Australia Pty. Ltd....
Items per page:
1 - 10 of 53
BioCentury | Nov 26, 2018
Distillery Therapeutics

Cardiovascular

...Pharmaceutical Co. Ltd., Gruppo Angelini, Incyte Corp., Medison Pharma Ltd., Otsuka Pharmaceutical Co. Ltd. and Specialised Therapeutics Australia Pty. Ltd....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...treatment-naïve patients PDUFA date September PharmaMar S.A. (Madrid:PHM) / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Specialised Therapeutics Australia Pty. Ltd....
BioCentury | May 30, 2018
Distillery Therapeutics

Neurology

...testing additional stabilizers of FAM9B G-quadruplex DNA in humanized models of ATR-X. Medac GmbH and Specialised Therapeutics Australia Pty. Ltd....
BioCentury | Mar 27, 2018
Distillery Therapeutics

Cancer; inflammation

...Pharmaceutical Co. Ltd., Gruppo Angelini, Incyte Corp., Medison Pharma Ltd., Otsuka Pharmaceutical Co. Ltd. and Specialised Therapeutics Australia Pty. Ltd....
BioCentury | Mar 13, 2018
Distillery Therapeutics

Cancer

...conjugate in additional models of TNBC. Celgene Corp., BeiGene Ltd., Biocon Ltd., Green Cross Corp., Specialised Therapeutics Australia Pty. Ltd....
...Ltd. market Abraxane, an albumin-stabilized nanoparticle formulation of paclitaxel, to treat breast cancer. Celgene, BeiGene, Specialised Therapeutics Australia...
BioCentury | Jan 26, 2018
Clinical News

PharmaMar's Zepsyre misses in Phase III for platinum-resistant ovarian cancer

...its active state. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) has exclusive, Japanese rights to Zepsyre, while Specialised Therapeutics Australia Pty. Ltd....
...see BioCentury, Dec. 29, 2016 & June 8, 2017 ). PharmaMar S.A. (Madrid:PHM), Madrid, Spain Specialised Therapeutics Australia Pty. Ltd....
...overall response rate (ORR) Status: Phase III data Milestone: NA Jaime De Leon lurbinectedin PM01183 PM1183 Zepsyre Chugai Pharmaceutical Co. Ltd. PharmaMar S.A. Specialised Therapeutics Australia Pty. Ltd. RNA...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Additional Ph III data 1H18 PharmaMar S.A. (Madrid:PHM) / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Specialised Therapeutics Australia Pty. Ltd....
BioCentury | Nov 30, 2017
Clinical News

PharmaMar reports Phase II response data for Zepsyre in Ewing's sarcoma

...overall survival (OS). Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) has exclusive, Japanese rights to Zepsyre, while Specialised Therapeutics Australia Pty. Ltd....
...targeting RNA polymerase II (Pol II) in its active state. PharmaMar S.A. (Madrid:PHM), Madrid, Spain Specialised Therapeutics Australia Pty. Ltd....
...1-year overall survival (OS) Status: Phase II data Milestone: NA Jaime De Leon lurbinectedin PM01183 PM1183 Zepsyre Chugai Pharmaceutical Co. Ltd. PharmaMar S.A. Specialised Therapeutics Australia Pty. Ltd. RNA...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...acne vulgaris Submit NDA 4Q17 PharmaMar S.A. (Madrid:PHM) / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Specialised Therapeutics Australia Pty. Ltd....
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...panel; PDUFA date 7/11/17; September PharmaMar S.A. (Madrid:PHM) / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Specialised Therapeutics Australia Pty. Ltd....
Items per page:
1 - 10 of 53